Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Entrectinib - Roche

Drug Profile

Entrectinib - Roche

Alternative Names: Entrectinib - Ignyta; NMS-E628; RG 6268; Rozlytrek; RXDX-101; TrkA/TrkB/TrkC/ROS1/ALK inhibitor - Roche

Latest Information Update: 26 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nerviano Medical Sciences
  • Developer Alliance for Clinical Trials in Oncology; Chugai Biopharmaceuticals; Genentech; National Cancer Institute (USA); Roche; University of California at San Francisco
  • Class Antineoplastics; Benzamides; Fluorinated hydrocarbons; Indazoles; Piperazines; Pyrans; Small molecules; Tumour-agnostic therapies
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; ROS1 protein inhibitors; TrkA receptor antagonists; TrkB receptor antagonists; TrkC receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroblastoma; Colorectal cancer; Solid tumours; Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer; Solid tumours
  • Phase II Brain metastases; Malignant melanoma
  • Phase I/II Uveal melanoma
  • No development reported Acute myeloid leukaemia

Most Recent Events

  • 27 Feb 2024 Genentech completes a phase II trial in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (PO) (NCT04632992)
  • 20 Oct 2023 Pooled efficacy and adverse events data from the phase I STARTRK-1, phase I/II ALKA-372-001, and phase II STARTRK-2, TAPISTRY trial in Solid tumors presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
  • 11 Oct 2023 Efficacy and adverse events data from the phase II STARTRK-2 trial in Solid tumors presented at International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top